Biosimilar Patent Litigation: The Complete Prediction Framework for IP Teams and Portfolio Managers
I. What the Global Biosimilar Market Actually Looks Like Right Now The biosimilar market reached approximately USD 40.4 billion in […]
Can Drug Companies Bribe the FDA? Unveiling the Truth Behind Pharmaceutical Influence
FDA Regulatory Integrity and the Mechanics of Pharmaceutical Market Entry The relationship between pharmaceutical manufacturers and the Food and Drug
Can Drug Companies Bribe the FDA? Unveiling the Truth Behind Pharmaceutical Influence Read Post »
Predicting Drug Patent Litigation Outcomes
For pharma IP teams, portfolio managers, R&D leads, and institutional investors who need to read case trajectories — not just
Predicting Drug Patent Litigation Outcomes Read Post »
Drug Patent Lifecycle: The Complete Pharma IP Strategy Playbook
I. Executive Summary Pharmaceutical patents are not legal formalities. They are the single most important determinant of whether a drug
Drug Patent Lifecycle: The Complete Pharma IP Strategy Playbook Read Post »
Clinical Trial Pharmacists: The Complete Strategic Guide to Investigational Drug Services, Protocol Integrity, and Data Quality
For pharma IP teams, R&D leads, CROs, and portfolio managers who need more than a surface-level overview. Why Pharmacists Are
Off-Patent, Zero Competition: Why Some Off-Patent Drugs Have No Generic Rivals
The blueprint for drug competition is clean on paper. A company wins a 20-year patent, recovers its R&D investment during
Off-Patent, Zero Competition: Why Some Off-Patent Drugs Have No Generic Rivals Read Post »
How Pharma Reads Patent Filings to Predict Post-Expiration Revenue — And Defend It
I. The Core Problem: Effective Patent Life vs. Nominal Term The pharmaceutical business runs on a single structural tension: the
How Pharma Reads Patent Filings to Predict Post-Expiration Revenue — And Defend It Read Post »
Drug Patent Term Extension Beyond NCEs: The Complete Playbook for Biologics, Combinations, and Formulations
1. Why the NCE-Only Mental Model Is Costing You IP Value Key Takeaways The phrase ‘patent cliff’ has been overused
Multiple Patent Term Extensions: The Complete Playbook for Stacking Exclusivity on a Single Drug
Why Effective Patent Life Is the Only Number That Matters Every pharmaceutical deal, licensing negotiation, and portfolio valuation ultimately hinges
